Last reviewed · How we verify
HAIC of OXA — Competitive Intelligence Brief
phase 3
Platinum-based chemotherapy (regional delivery)
DNA (via platinum-DNA adduct formation)
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
HAIC of OXA (HAIC of OXA) — Sun Yat-sen University. HAIC of OXA delivers oxaliplatin directly into the hepatic artery to achieve high local chemotherapy concentration in liver tumors while minimizing systemic exposure.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HAIC of OXA TARGET | HAIC of OXA | Sun Yat-sen University | phase 3 | Platinum-based chemotherapy (regional delivery) | DNA (via platinum-DNA adduct formation) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Platinum-based chemotherapy (regional delivery) class)
- Sun Yat-sen University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HAIC of OXA CI watch — RSS
- HAIC of OXA CI watch — Atom
- HAIC of OXA CI watch — JSON
- HAIC of OXA alone — RSS
- Whole Platinum-based chemotherapy (regional delivery) class — RSS
Cite this brief
Drug Landscape (2026). HAIC of OXA — Competitive Intelligence Brief. https://druglandscape.com/ci/haic-of-oxa. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab